---
title: "普蕊斯(上海)醫藥科技開發股份有限公司 (301257.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301257.SZ.md"
symbol: "301257.SZ"
name: "普蕊斯(上海)醫藥科技開發股份有限公司"
industry: "生命科學工具與服務"
---

# 普蕊斯(上海)醫藥科技開發股份有限公司 (301257.SZ)

| Item | Detail |
|------|--------|
| Industry | 生命科學工具與服務 |
| Location | 滬深市場 |
| Website | [www.smo-clinplus.com](https://www.smo-clinplus.com) |

## Company Profile

公司順應中國 SMO 行業發展趨勢，滿足國內創新藥企臨床需求，提升臨床研究效率。2013 年公司成立，2022 年 5 月 17 日成功登陸創業板。公司通過深度解構臨床試驗和醫院實際場景，創建出一套臨床試驗全流程項目管理體系。我們專注于為全球制藥公司、醫療器械公司、CRO 公司等提供高效、合規的臨床試驗現場管理組織 (SMO) 服務，幫助客戶提升臨床試驗的執行效率和數據質量，助力新藥更快惠及患者。公司提供的主要主要產品及服務有前期建模、前期準備計劃、試驗點啟動、現場執行、項目全流程管理。企業榮譽:2021 年年度上海市 “專精特新” 企業、黃浦區企業技術中心、上海市科技小巨人企業、高新技術企業...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:09.000Z

**Overall: B (0.36)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 9 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.14% |  |
| Net Profit YoY | 14.58% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.33 |  |
| Dividend Ratio | 0.25% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.42B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 819.11M |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.16% | B |
| Profit Margin | 14.84% | A |
| Gross Margin | 29.11% | C |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.14% | C |
| Net Profit YoY | 14.58% | C |
| Total Assets YoY | 8.91% | B |
| Net Assets YoY | 9.80% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 673.89% | C |
| OCF YoY | 1.14% | C |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.57 | B |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 16.69% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 普蕊斯(上海)醫藥科技開發股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.16%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "14.84%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "29.11%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.14%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "14.58%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.91%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.80%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "673.89%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1.14%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.57",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "16.69%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 藥明康德 (SH.603259) | A | A | C | B | B | B |
| 02 | 康龍化成 (SZ.300759) | B | B | C | C | B | B |
| 03 | 皓元醫藥 (SH.688131) | B | A | C | C | B | B |
| 04 | 成都先導 (SH.688222) | B | B | D | B | B | B |
| 05 | 賽分科技 (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 44.58 | 4/27 | 35.85 | 30.76 | 24.42 |
| PB | 4.33 | 21/27 | 3.17 | 2.74 | 2.07 |
| PS (TTM) | 6.61 | 9/27 | 4.81 | 4.06 | 3.02 |
| Dividend Yield | 0.25% | 12/27 | 0.90% | 0.58% | 0.25% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-05-05T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 68.58 |
| Highest Target | 27.51 |
| Lowest Target | 27.51 |

## References

- [Company Overview](https://longbridge.com/en/quote/301257.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301257.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301257.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.